The Scan

The Washington Post reports on SARS-CoV-2 viral variants among immunocompromised COVID-19 patients.

Bluebird Bio finds the modified virus used in its gene therapy is unlikely to be the cause of a patient's leukemia, according to Science.

The World Health Organization is still figuring out how to handle the pandemic a year on, the Associated Press writes.

Reuters reports that a new study indicates the B.1.1.7 variant of SARS-CoV-2 is more deadly than previously circulating variants.

Florida Politics reports on a proposed bill there that would require informed and written consent for collecting DNA or disclosing results of genetic analyses.

After finding rare genetic variants that could have contributed to her children's death, a petition calls for the pardon and release of Kathleen Folbigg, the Sydney Morning Herald reports.

According to the New York Times, the COVID-19 pandemic has led to fewer US Food and Drug Administration inspections of drug companies.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.